Andrew S. Robertson is currently the Director of Global Regulatory Policy at Merck & Co., where he focuses on U.S. and international regulatory policies affecting complex molecules, such as vaccines, biologics/biosimilars, and in vitro diagnostics. Andrew is also a visiting scholar at the University of California, Berkeley, where he researches policy issues in synthetic biology, personalized medicine, and global health. Prior to joining Merck, Andrew worked as an IP litigation attorney in the life sciences practice of Jones Day, Silicon Valley.
Over the past ten years, Andrew has developed a broad career in life sciences law and policy. His experience includes a faculty research position in genetics at the Wellcome Trust Sanger Centre, a AAAS S&T Policy Fellowship at the U.S. Department of Health & Human Services, Office of the Secretary, and serving as the Chief Policy Officer at BIO Ventures for Global Health. He has authored multiple peer-reviewed articles on topics pertaining to health and innovation policy, such as the FDA priority review voucher, social enterprises in global health drug discovery, and regulation policies concerning in vitro diagnostics. Andrew sits on numerous national panels, and chairs the American Bar Association Committee for the Rights and Responsibilities of Sciences.
Andrew holds a JD from UC Berkeley, School of Law, a Ph.D. in structural biology from Cambridge University (w/ distinction), and a MS and BS in genetics from UC San Diego. Andrew is an alum of the Gates Cambridge Scholarship program (’01), and currently sits on the Gates Cambridge Board of Trustees.
- No sessions found